

LETTER TO SHAREHOLDERS

July 15, 2022

Dear Emerald Health Therapeutics, Inc. Shareholders:

You are invited to attend an annual general and special meeting (the "**Meeting**") of holders (the "**EHT Shareholders**") of common shares ("**EHT Shares**") in the capital of Emerald Health Therapeutics, Inc. ("**EHT**").

The Meeting will be held virtually via live audio webcast at <https://meetnow.global/MHYHWGA> on August 19, 2022 at 10:00am (Vancouver time).

The Arrangement

At the Meeting, EHT Shareholders will be asked to consider and, if thought advisable, approve, with or without variation, a special resolution (the "**Arrangement Resolution**"), with respect to the plan of arrangement pursuant to the *Business Corporations Act* (British Columbia) (the "**Arrangement**") involving, among other things, the acquisition by Skye Bioscience, Inc. ("**SKYE**") of all of the outstanding EHT Shares pursuant to an arrangement agreement dated May 11, 2022, between EHT and SKYE, as subsequently amended.

Under the Arrangement, as more particularly described in the accompanying management information circular (the "**Circular**"), each EHT Shareholder that has not validly exercised dissent rights in accordance with the Arrangement will receive at the effective time of the Arrangement, for each EHT Share held, 1.95 (the "**Exchange Ratio**") shares of common stock of SKYE ("**SKYE Shares**").

On completion of the Arrangement, former EHT Shareholders are expected to hold 46% of the outstanding SKYE Shares and current shareholders of SKYE are expected to hold the remaining 54% of the outstanding SKYE Shares.

Voting Requirements

To become effective, the Arrangement Resolution must be approved by at least (a) 66 2/3% of the votes cast on the Arrangement Resolution by EHT Shareholders present in person or represented by proxy and entitled to vote at the Meeting; and (b) a majority of the votes cast on the Arrangement Resolution by EHT Shareholders present in person or represented by proxy and entitled to vote at the Meeting, excluding votes attached to the EHT Shares that are required to be excluded pursuant to MI 61-101.

The Arrangement also requires the approval of the Supreme Court of British Columbia and the shareholders of SKYE as more particularly described in the Circular. In addition to shareholder, court and regulatory approvals, the Arrangement is subject to certain other closing conditions customary in transactions of this nature which are described in the Circular.

Background to the Arrangement

In November 2021, the board of directors of EHT (the "**EHT Board**") initiated a detailed review of EHT's cannabis business and after considering a number of factors, including the state of the current recreational and medicinal cannabis market in Canada, EHT's continuing losses and eroding of capital,

investor interest, potential exit strategies from the cannabis space and other matters, the EHT Board determined that it was in the best interest of EHT to exit the recreational and medicinal cannabis sector and to pivot to a cannabinoid pharmaceutical development focus. In connection with this determination, the EHT Board began considering potential merger and acquisition alternatives.

On November 21, 2021, the EHT Board engaged Vantage Point Advisors, Inc. ("**Vantage Point**") of San Diego, California to carry out a thorough review of companies in Canada and the United States engaged in the cannabinoid pharmaceutical development of product candidates that may be interested in carrying out a strategic merger with EHT. The EHT Board asked Vantage Point to focus on this sector as the EHT Board has significant experience, and numerous contacts, in the areas of cannabinoid science and pharmaceutical development. Vantage Point identified and analysed 21 companies in this sector, including SKYE, and presented a short list of ten companies to the EHT Board. Pursuant to discussions between Vantage Point and EHT, the short list was decreased to seven companies and Vantage Point reached out to each of these companies to determine whether there was interest in a strategic transaction with EHT. Between November 2021 and February 2022, the EHT Board met with and carried out initial due diligence with respect to several potential targets. EHT conducted an initial due diligence review and financial analysis of all the targets, including SKYE, with the assistance and advice of Vantage Point.

Voting Agreements

Emerald Health Sciences, Inc. and all senior officers and directors of EHT, who collectively have voting ownership of approximately 19% of the EHT Shares, have entered into support agreements with SKYE in support of the Arrangement.

Board Recommendation

The EHT Board has unanimously determined that the Arrangement is in the best interests of EHT and has unanimously approved the Arrangement and recommends that EHT Shareholders vote FOR the Arrangement Resolutions.

In making their determinations, the EHT Board considered, among other things, the recommendation of the special committee of EHT formed to consider the Arrangement and a fairness opinion delivered by Evans & Evans, Inc. ("**Evans & Evans**") to the effect that, based upon and subject to the assumptions, limitations and qualifications set out therein and such other matters as Evans & Evans considered relevant, Evans & Evans was of the opinion that, as of the date of such opinion, the Arrangement and the Exchange Ratio are fair, from a financial point of view, to the EHT Shareholders. A copy of Evans & Evans's fairness opinion is attached as Appendix "E" to the attached Circular.

The Circular and the documents incorporated by reference therein contain a detailed description of the Arrangement and other information relating to EHT and SKYE. We urge you to carefully consider all of the information in the Circular and the documents incorporated by reference therein. If you require assistance, please consult your financial, legal or other professional advisors.

Vote Your EHT Shares Today for the Arrangement Resolutions

If you have any questions with regard to the procedures for voting or completing your transmittal documentation, please contact Bernie Hertel: bhertel@emeraldhealth.ca.

This is an important matter affecting the future of EHT and your vote is important regardless of the number of EHT Shares you own. If you are a registered EHT Shareholder and are unable to attend the Meeting virtually in person, we encourage you to vote by completing the enclosed forms of proxy or, alternatively, by telephone, or over the internet, in each case in accordance with the enclosed instructions. Voting by proxy will not prevent you from voting virtually in person if you attend the Meeting and will ensure that your vote will be counted if you are unable to attend.

An EHT Shareholder proxy will not be valid for use at the Meeting unless the completed form of proxy is deposited at the offices of Computershare Investor Services Inc., 100 University Avenue, 8th Floor, Toronto, Ontario M5J 2Y1, in the enclosed envelope, by mail, courier or hand delivery by 10:00 a.m. (Vancouver time) on August 17, 2022 (or at least 48 hours (excluding non-Business Days) prior to any reconvened meeting in the event of an adjournment or postponement of the Meeting). Alternatively, EHT Shareholders may vote by telephone (1-866-732-8683) or online (www.investorvote.com) using the control number listed on the proxy.

Registered Shareholder Information

We also encourage all registered EHT Shareholders to complete and return the enclosed letter of transmittal ("**Letter of Transmittal**"), together with the certificate(s) (if applicable) representing your EHT Shares, to Computershare Investor Services Inc. (the "**Depository**") at the address specified in the Letter of Transmittal. The Letter of Transmittal contains procedural information relating to the Arrangement and should be reviewed carefully. We recommend that you complete, sign and return the Letter of Transmittal with your EHT certificate(s) (if applicable) to the Depository by no later than 10:00 a.m. (Vancouver time) on August 17, 2022.

Non-Registered Holder Information

If you are a non-registered holder of EHT Shares and have received these materials through your broker, investment dealer or other intermediary, you will not receive a form of proxy or Letter of Transmittal, as applicable. Please follow the instructions provided by such broker, investment dealer or other intermediary to ensure that your vote is counted at the Meeting and for instructions and assistance in delivering the share certificate(s) (if applicable) representing your EHT Shares. See "*Virtual Meeting Voting Instructions*" as Appendix "I" to the attached Circular.

Subject to obtaining court and other approvals, and the satisfaction or waiver of all other conditions precedent to the Arrangement, if the EHT Shareholders approve the Arrangement Resolution, it is anticipated that the Arrangement will be completed in the fourth quarter of 2022. Thank you for your ongoing support as we move to carry out this transformative step for EHT.

BY ORDER OF THE BOARD OF DIRECTORS

"Jim Heppell"

Jim Heppell
Chairman